Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV001096145 | SCV001252335 | likely benign | Hereditary motor and sensory neuropathy with optic atrophy | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV001096146 | SCV001252336 | likely benign | Charcot-Marie-Tooth disease type 2 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Labcorp Genetics |
RCV001096146 | SCV002442984 | likely benign | Charcot-Marie-Tooth disease type 2 | 2024-07-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002418579 | SCV002725591 | uncertain significance | Inborn genetic diseases | 2021-06-12 | criteria provided, single submitter | clinical testing | The p.V69I variant (also known as c.205G>A), located in coding exon 2 of the MFN2 gene, results from a G to A substitution at nucleotide position 205. The valine at codon 69 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the supporting evidence, this variant is unlikely to be causative of autosomal dominant MFN2-related neuropathy; however, its contribution to the development of autosomal recessive MFN2-related neuropathy is uncertain. |